TITLE

In Vitro Antimicrobial Findings for Fusidic Acid Tested Against Contemporary (2008–2009) Gram-Positive Organisms Collected in the United States

AUTHOR(S)
Jones, Ronald N.; Mendes, Rodrigo E.; Sader, Helio S.; Castanheira, Mariana
PUB. DATE
April 2011
SOURCE
Clinical Infectious Diseases;2011, Vol. 52 Issue Suppl 7, pS477
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Fusidic acid has a long history of consistent activity against staphylococcal pathogens including methicillin-resistant Staphylococcus aureus (MRSA). Fusidic acid (CEM-102) was susceptibility tested against a surveillance study collection of 12,707 Gram-positive pathogens (2008–2009) from the United States. Reference broth microdilution method results demonstrated the following MIC50/90 results: S. aureus (.12/.25 μg/mL), coagulase-negative staphylococci (.12/.25 μg/mL), enterococci (4/4 μg/mL), Streptococcus pyogenes (4/8 μg/mL), and viridans group Streptococcus spp. (>8/>8 μg/mL). At a proposed susceptible breakpoint (≤1 μg/mL), fusidic acid inhibited 99.7% of MRSA strains and 99.3% to 99.9% of multidrug-resistant phenotypes of S. aureus. Furthermore, S. aureus strains nonsusceptible to fusidic acid (.35%) generally had detectable resistance mechanisms (fusA, B, C, and E). Reviews of in vitro susceptibility test development confirm the accuracy and intermethod reproducibility of various fusidic acid methods. Fusidic acid is a promising oral therapy for staphylococcal skin and skin structure infections in the United States, where the contemporary S. aureus population remains without significant resistance.
ACCESSION #
83182349

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics